Palvella Therapeutics Inc/$PVLA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Palvella Therapeutics Inc
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
Ticker
$PVLA
Sector
Primary listing
Employees
14
Headquarters
Website
PVLA Metrics
BasicAdvanced
$789M
-
-$4.08
-
-
Price and volume
Market cap
$789M
52-week high
$77.77
52-week low
$18.23
Average daily volume
201K
Financial strength
Current ratio
7.669
Quick ratio
7.53
Long term debt to equity
30.37
Total debt to equity
30.37
Interest coverage (TTM)
-5.20%
Profitability
Management effectiveness
Return on assets (TTM)
-37.25%
Return on equity (TTM)
-151.15%
Valuation
Price to book
16.5
Price to tangible book (TTM)
16.5
Price to free cash flow (TTM)
-24.042
Free cash flow yield (TTM)
-4.16%
Free cash flow per share (TTM)
-2.966
Growth
Earnings per share change (TTM)
627.20%
Bulls say / Bears say
The Phase 3 SELVA trial surpassed its enrollment target by more than 25% (51 vs. 40 subjects), demonstrating strong patient and investigator interest as well as efficient study execution.
QTORIN™ rapamycin has FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations, which are likely to speed up its development, regulatory review, and provide market exclusivity benefits.
As of March 31, 2025, Palvella reported $75.6 million in cash and cash equivalents, giving it financial runway into the second half of 2027 and reducing immediate financing risk.
QTORIN™ rapamycin is still unapproved and top-line Phase 3 SELVA trial data won't be available until the first quarter of 2026, posing significant regulatory risk before any potential commercialization.
The Phase 2 TOIVA trial for cutaneous venous malformations will only deliver top-line results in the fourth quarter of 2025, delaying possible label expansion and diversification of revenue.
Research and development expenses increased to $4.1 million in Q1 2025 from $1.0 million the previous year, accelerating the cash burn rate and potentially shortening the company's cash runway if clinical costs keep rising.
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Palvella Therapeutics Inc stock?
Palvella Therapeutics Inc (PVLA) has a market cap of $789M as of October 24, 2025.
What is the P/E ratio for Palvella Therapeutics Inc stock?
The price to earnings (P/E) ratio for Palvella Therapeutics Inc (PVLA) stock is 0 as of October 24, 2025.
Does Palvella Therapeutics Inc stock pay dividends?
No, Palvella Therapeutics Inc (PVLA) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next Palvella Therapeutics Inc dividend payment date?
Palvella Therapeutics Inc (PVLA) stock does not pay dividends to its shareholders.
What is the beta indicator for Palvella Therapeutics Inc?
Palvella Therapeutics Inc (PVLA) does not currently have a Beta indicator.